Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer’s Dementia at AAIC 2022
Researchers to highlight positive results from a phase 3 clinical study for treatment of agitation in patients with Alzheimer’s dementia PRINCETON, N.J. & DEERFIELD, Ill.–(BUSINESS WIRE)–Otsuka Pharmaceutical Development & Commercialization, Inc., and H. Lundbeck A/S (Lundbeck) today announce that new Phase 3 data for brexpiprazole will be presented at the 2022 Alzheimer’s Association International Conference … [Read more…]